MARKET

ERNA

ERNA

Ernexa
NASDAQ
3.848
+0.228
+6.30%
Opening 10:37 09/25 EDT
OPEN
3.610
PREV CLOSE
3.620
HIGH
3.848
LOW
3.610
VOLUME
1.38K
TURNOVER
--
52 WEEK HIGH
71.50
52 WEEK LOW
3.183
MARKET CAP
6.28M
P/E (TTM)
-0.2059
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ERNA last week (0914-0918)?
Weekly Report · 4d ago
Press Release: Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Dow Jones · 09/17 12:42
Eterna Therapeutics Updates Investors With New Corporate Materials
TipRanks · 09/16 21:57
Eterna Therapeutics appoints independent director Robert J. Spiegel
TipRanks · 09/16 21:18
Ernexa reports preliminary results for ERNA-201, to focus resources on ERNA-101
TipRanks · 09/15 13:06
Ernexa Reports Positive ERNA-201 Preclinical Data; Advances ERNA-101 Toward Q4 2026 IND
NASDAQ · 09/15 12:53
Weekly Report: what happened at ERNA last week (0907-0911)?
Weekly Report · 09/14 10:18
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 09/14 08:05
More
About ERNA
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Webull offers Ernexa Therapeutics Inc stock information, including NASDAQ: ERNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERNA stock methods without spending real money on the virtual paper trading platform.